OSU-T315 (15-regioisomer)

CAS No. 2070015-22-2

OSU-T315 (15-regioisomer)( ILK-IN-2 )

Catalog No. M20219 CAS No. 2070015-22-2

OSU-T315 (15-regioisomer) is a ILK inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 132 In Stock
5MG 222 In Stock
10MG 357 In Stock
25MG 614 In Stock
50MG 872 In Stock
100MG 1161 In Stock
500MG 2367 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    OSU-T315 (15-regioisomer)
  • Note
    Research use only, not for human use.
  • Brief Description
    OSU-T315 (15-regioisomer) is a ILK inhibitor.
  • Description
    OSU-T315 (15-regioisomer) is a ILK inhibitor.
  • In Vitro
    OSU-T315 (Compound 22; 0-5 μM; 24 hours) exhibits high in vitro potency against a panel of prostate and breast cancer cell lines with a IC50 range of 1-2.5 μM.?OSU-T315 (0-2.5 μM; 24 hours) can reduce YB-1, HER2, and EGFR expression; shows a modest suppressive effect on phosphorylated S6 levels, exhibits dose-dependent suppressive effects on the levels of phospho-ERK1/2 and phospho-p38, while that of phospho-JNK remains unaltered in PC-3 cell. OSU-T315 (0-4 μM; 24 hours) causes autophagy through ILK inhibition. Western Blot Analysis Cell Line:PC-3 cells; MDA-MB-231 cells Concentration:1 μM, 2 μM, 3 μM, 4 μM; 0.5 μM, 1 μM, 1.5 μM, 2 μM, 2.5 μM Incubation Time:24 hours Result:Exhibited a dose-dependent decreasing effect on the phosphorylation of pS6, ERKs, and p38 in PC-3 cells and MDA-MB-231 cells.Cell Viability Assay Cell Line:Prostate cancer cells: LNCaP, PC-3; breast cancer cells: MDA-MB-231, MDA-MB-468, SKBR3, MCF-7; PrEC and MEC cells Concentration:0-5 μM Incubation Time:24 hours Result:Suppressed cancer cells viability in breast and prostate cancer cells (IC (50), 1-2.5μM).Apoptosis Analysis Cell Line:PC-3 cells Concentration:1 μM, 2 μM, 3 μM, 4 μM Incubation Time:24 hours Result:Induced accumulation of LC3-II and PARP cleavage.
  • In Vivo
    OSU-T315 (Oral gavage; 25 mg/kg, 50 mg/kg; single daily; 35 days) has a suppressive effect of on PC-3 xenograft tumor growth . No other obvious toxicity is observed in mice. Animal Model: Male NCr athymic nude mice with PC-3 tumor xenografts Dosage:25 mg/kg; 50 mg/kg Administration:Oral gavage; single daily; 35 days Result:Resulted in suppression of tumor growth relative to the vehicle control after 35 days of treatment (48% and 62% suppression for 25 and 50 mg/kg, respectively).
  • Synonyms
    ILK-IN-2
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    Integrin
  • Recptor
    ILK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2070015-22-2
  • Formula Weight
    533.6
  • Molecular Formula
    C30H30F3N5O
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:50 mg/mL?(93.70 mM)
  • SMILES
    CNC(=O)CCc1cc(nn1-c1ccc(cc1)N1CCNCC1)-c1ccc(cc1)-c1ccc(cc1)C(F)(F)F
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Lee SL et al. Identification and characterization of a novel integrin-linked kinase inhibitor. J Med Chem. 2011 Sep 22;54(18):6364-74.
molnova catalog
related products
  • Cilengitide

    Cilengitide is a potent integrin inhibitor for αvβ3 receptor and αvβ5 receptor with IC50 of 4.1 nM and 79 nM in cell-free assays, respectively; ~10-fold selectivity against gpIIbIIIa. Phase 2.

  • PLN-1474

    PLN-1474 is a potent αVβ1 inibitor with IC50 < 50nM (WO2021127483, compound 1)

  • P11

    Potent antagonist of the integrin αvβ3-vitronectin interaction (IC50 = 25.72 nM). Blocks proliferation and induces apoptosis in HUVECs; antiangiogenic.